The effectiveness of the use of flavonoids in the complex treatment of psoriasis in patients with grade I-II alimentary obesity

Abstract

Psoriasis is one of the chronic dermatoses with unexplained pathogenesis and significant prevalence among the population. Chronic and often severe course of the disease leads to disability, and sometimes to disability [1]. The lack of a clear understanding of the etiology and pathogenesis makes it possible to attribute this dermatosis to the most important medical and economic health problems [8]. It is believed that psoriasis refers to genetically determined diseases with predominant skin damage, which is associated with impaired keratinocyte proliferation and the development of inflammatory processes [2]. An undoubted relationship between psoriasis and obesity has been established [3]. In the literature, the question of identical pathogenetic mechanisms of inflammatory processes in psoriasis and obesity, forming a vicious circle at the level of the immune system, which must be broken for the successful treatment of these diseases, is widely covered [4]. Obesity can be either an independent multifactorial disease - primary obesity (alimentary-constitutional), or the syndrome accompanying the course of other diseases - secondary obesity (symptomatic). In the structure of morbidity, primary obesity occurs in 95% of patients, secondary - only in 5% [7,9]. A person is considered obese if the body mass index (BMI) exceeds 30 kg / m². According to the results of previous studies, we found that alimentary obesity in patients with psoriasis leads to metabolic disorders complicating the course of dermatosis, leading to the ineffectiveness of standard methods of therapy and frequent exacerbations of psoriatic disease [5].